Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function
Joint Authors
Anderson, Ronald
Theron, A. J.
Tintinger, G. R.
Gravett, C. M.
Feldman, Charles
Steel, Helen C.
Source
Journal of Immunology Research
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-05-25
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
Cysteinyl leukotrienes (cysLTs) are produced predominantly by cells of the innate immune system, especially basophils, eosinophils, mast cells, and monocytes/macrophages.
Notwithstanding potent bronchoconstrictor activity, cysLTs are also proinflammatory consequent to their autocrine and paracrine interactions with G-protein-coupled receptors expressed not only on the aforementioned cell types, but also on Th2 lymphocytes, as well as structural cells, and to a lesser extent neutrophils and CD8+ cells.
Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast.
More recently these agents have also been reported to possess secondary anti-inflammatory activities, distinct from cysLTR1 antagonism, which appear to be particularly effective in targeting neutrophils and monocytes/macrophages.
Underlying mechanisms include interference with cyclic nucleotide phosphodiesterases, 5′-lipoxygenase, and the proinflammatory transcription factor, nuclear factor kappa B.
These and other secondary anti-inflammatory mechanisms of the commonly used cysLTR1 antagonists are the major focus of the current review, which also includes a comparison of the anti-inflammatory effects of montelukast, pranlukast, and zafirlukast on human neutrophils in vitro, as well as an overview of both the current clinical applications of these agents and potential future applications based on preclinical and early clinical studies.
American Psychological Association (APA)
Theron, A. J.& Steel, Helen C.& Tintinger, G. R.& Gravett, C. M.& Anderson, Ronald& Feldman, Charles. 2014. Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function. Journal of Immunology Research،Vol. 2014, no. 2014, pp.1-16.
https://search.emarefa.net/detail/BIM-1040920
Modern Language Association (MLA)
Theron, A. J.…[et al.]. Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function. Journal of Immunology Research No. 2014 (2014), pp.1-16.
https://search.emarefa.net/detail/BIM-1040920
American Medical Association (AMA)
Theron, A. J.& Steel, Helen C.& Tintinger, G. R.& Gravett, C. M.& Anderson, Ronald& Feldman, Charles. Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function. Journal of Immunology Research. 2014. Vol. 2014, no. 2014, pp.1-16.
https://search.emarefa.net/detail/BIM-1040920
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1040920